Lincoln Pharmaceuticals Limited has reported a quantum jump in net profit and turnover during the nine months which ended on 31.12.2002. Net profit has increased from Rs. 94 lakh to Rs. 203 lakh with 115 per cent growth during the nine months ended on 31.12.2002 and achieved a turn over of Rs. 2673 lakh, which is up by 25 per cent as compared to corresponding period of last year.

The Company is ethically marketing its products through out India. Export remains a major thrust area. Company constantly upgrade their facilities to meet international competition. Currently the company's manufacturing facilities hold the WHO GMP & ISO 9002 certification. Lincoln's products are registered and marketed in Kenya, Zambia, Uganda, Ghama, Tanzania, Zimbabwe, Rwanda, Somalia etc.

Continuous R&D is the essence of pharma company and in view of that Lincoln has set-up its own recognized R&D unit at Khatraj Plot, which has been recognized by The Department of Scientific & Industrial Research, Ministry of Science & Technology, Government of India.

Lincoln holds WHO GMP & ISO 9002 certification. Hence a platform for further approval by M.C.A. of UK an US-FDA has been created. Company is set to meet new millennium and face challenges offered by WTO agreement.